摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

英丙舒凡对甲苯磺酸盐 | 32784-82-0

中文名称
英丙舒凡对甲苯磺酸盐
中文别名
——
英文名称
Improsulfan p-toluenesulfonate
英文别名
bis(3-methylsulfonyloxypropyl)azanium;4-methylbenzenesulfonate
英丙舒凡对甲苯磺酸盐化学式
CAS
32784-82-0
化学式
C15H27NO9S3
mdl
——
分子量
461.6
InChiKey
XQGSVNHIIVBMPX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    113-118°

计算性质

  • 辛醇/水分配系数(LogP):
    0.55
  • 重原子数:
    28
  • 可旋转键数:
    11
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    178
  • 氢给体数:
    2
  • 氢受体数:
    10

文献信息

  • MORPHOLINOPURINE DERIVATIVES
    申请人:Nakayama Kiyoshi
    公开号:US20100130492A1
    公开(公告)日:2010-05-27
    There is provided a novel compound that inhibits phosphatidylinositol 3-kinase (PI3K) and/or the mammalian target of rapamycin (mTOR) and exhibits anti-tumor activity. The present invention provides a compound represented by the following formula (1) having various substituents that inhibits PI3K and/or mTOR and exhibits anti-tumor activity: wherein R 1 , R 2 , R 3 , R 4 , R a , R b , R c , and X each have the same meaning as defined in the specification.
    提供了一种新型化合物,它抑制磷脂酰肌醇3-激酶(PI3K)和/或哺乳动物雷帕霉素靶蛋白(mTOR),并表现出抗肿瘤活性。本发明提供了一种由以下式(1)表示的化合物,具有各种取代基,可抑制PI3K和/或mTOR,并表现出抗肿瘤活性: 其中R1、R2、R3、R4、Ra、Rb、Rc和X的含义与规范中定义的含义相同。
  • [EN] FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES FUSIONNÉS ET LEUR UTILISATION
    申请人:TAKEDA PHARMACEUTICAL
    公开号:WO2009136663A1
    公开(公告)日:2009-11-12
    The present invention provides a fused heterocyclic derivative having a strong kinase inhibitory activity and use thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.
    本发明提供了一种具有强烈激酶抑制活性的融合杂环衍生物及其用途。本发明涉及本说明书中所定义的符号表示的化合物,或其盐。
  • [EN] NITROGEN-CONTAINING HETEROCYCLIC COMPOUND<br/>[FR] COMPOSÉ HÉTÉROCYCLIQUE CONTENANT DE L'AZOTE
    申请人:TAKEDA PHARMACEUTICAL
    公开号:WO2013018929A1
    公开(公告)日:2013-02-07
    The present invention provides a novel compound having a superior activity as an ERR-α modulator and useful as an agent for the prophylaxis or treatment of ERR-α associated diseases. The present invention relates to a compound represented by the formula (1) wherein each symbol is as defined in the specification, or a salt thereof.
    本发明提供了一种新型的化合物,作为一种ERR-α调节剂具有优越的活性,并可作为预防或治疗与ERR-α相关疾病的药物。本发明涉及一种由公式(1)表示的化合物,其中每个符号如说明书中所定义,或其盐。
  • Pyrrolopyridinylpyrimidin-2-ylamine derivatives
    申请人:Wucherer-Plietker Margarita
    公开号:US20110218198A1
    公开(公告)日:2011-09-08
    Compounds of the formula I in which X, R 1 , R 2 , R 3 , R 4 and R 6 have the meanings indicated in Claim 1 , are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours.
    公式I中X、R1、R2、R3、R4和R6具有权利要求书中指示的含义,是细胞增殖/细胞活力的抑制剂,可用于肿瘤的治疗。
  • FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF
    申请人:Sakai Nozomu
    公开号:US20090137595A1
    公开(公告)日:2009-05-28
    The present invention provides a fused heterocyclic derivative having a potent kinase inhibitory activity and use thereof. A compound represented by the formula (I): wherein each symbol is as defined in the specification, except a particular compound, or a salt thereof, and a pharmaceutical agent containing the compound or a prodrug thereof, which is a kinase (VEGFR, VEGFR2, PDGFR, Raf) inhibitor, an angiogenesis inhibitor, an agent for the prophylaxis or treatment of cancer, a cancer growth inhibitor or a cancer metastasis suppressor.
    本发明提供了一种具有强大激酶抑制活性的融合杂环衍生物及其用途。 一种由以下式(I)表示的化合物: 其中除了特定化合物或其盐外,每个符号如规范中定义,以及含有该化合物或其前药的药用剂,该化合物是激酶(VEGFR、VEGFR2、PDGFR、Raf)抑制剂,血管生成抑制剂,用于癌症的预防或治疗的药剂,癌症生长抑制剂或癌症转移抑制剂
查看更多